Genky DrugStores Co., Ltd.
Stock Price Chart
2026/03/03 UpdatedPrice Trend
2026/03/03 UpdatedPrice & Trading Details
2026/03/03 UpdatedPRICE
TRADING
Analyst Recommendations 2 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Dividend History
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥13 | 0.0% |
| 2024 | ¥13 | +4.0% |
| 2023 | ¥13 | 0.0% |
| 2022 | ¥13 | 0.0% |
| 2021 | ¥13 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥154,639M | ¥169,059M | ¥184,860M | ¥200,786M |
| Gross Profit | ¥30,954M | ¥34,553M | ¥37,620M | ¥40,889M |
| Operating Income | ¥5,675M | ¥6,709M | ¥9,015M | ¥9,658M |
| Pretax Income | ¥6,142M | ¥6,774M | ¥8,906M | ¥10,118M |
| Net Income | ¥4,420M | ¥4,764M | ¥6,324M | ¥7,066M |
| EPS | ¥145.44 | ¥156.79 | ¥207.94 | ¥232.04 |
| Operating Margin | 3.67% | 3.97% | 4.88% | 4.81% |
| Balance Sheet | ||||
| Total Assets | ¥97,118M | ¥105,912M | ¥113,939M | ¥127,326M |
| Total Equity | ¥36,232M | ¥40,680M | ¥46,679M | ¥53,427M |
| Total Liabilities | ¥60,886M | ¥65,232M | ¥67,260M | ¥73,899M |
| Cash | ¥5,438M | ¥5,329M | ¥5,896M | ¥6,221M |
| Interest-bearing Debt | ¥30,959M | ¥32,354M | ¥30,648M | ¥34,374M |
| Equity Ratio | 37.31% | 38.41% | 40.97% | 41.96% |
| D/E Ratio | 0.85 | 0.80 | 0.66 | 0.64 |
| Cash Flow | ||||
| Operating CF | ¥6,076M | ¥8,773M | ¥13,256M | ¥12,597M |
| Investing CF | -¥10,588M | -¥9,736M | -¥10,631M | -¥15,618M |
| Financing CF | ¥2,037M | ¥854M | -¥2,058M | ¥3,346M |
| Free CF | -¥4,430M | -¥1,155M | ¥2,815M | -¥2,510M |
| Efficiency | ||||
| ROE | 12.20% | 11.71% | 13.55% | 13.23% |
| ROA | 4.55% | 4.50% | 5.55% | 5.55% |
Latest IR Information
-
Monthly Sales Report for February 2026 Fiscal Year Ending June
For February 2026, total store sales increased 7.2% year-over-year, existing store sales were flat at 100.0%, with 3 new store openings and no closures.
Read more -
Supplementary Materials for the Fiscal Year Ending June 2026 Financial Results
For the fiscal year ending June 2026, net sales were JPY 221.2 billion, up 10.2% YoY; operating income was JPY 11.05 billion, up 14.45% YoY; and net income was JPY 7.85 billion, up 11.15% YoY.
Read more -
Monthly Sales Update for January, Fiscal Year Ending June 2026
For January 2026, total store sales were 105.7% YoY, existing stores 98.6%, with one new store opened, bringing the total number of stores to 500.
Read more -
Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending June 2026 [Japanese Standards] (Consolidated)
For the second quarter of the fiscal year ending June 2026, net sales were JPY 109,261 million (10.6% YoY increase), operating income was JPY 5,717 million (24.4% YoY increase), and net income attributable to owners of parent was JPY 4,020...
Read more -
FY2026 Q2 Financial Results Presentation Materials
For FY2026 Q2, net sales amounted to 53.218 billion yen, a 9.3% increase year-over-year, operating income was 2.801 billion yen, up 20.6%, and the full-year earnings guidance has been revised upward to sales of 221.2 billion yen and operating income...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥5,700
Rating Score: 1.00 (Based on 2 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Genky DrugStores Co., Ltd. engages in the management and operation of food and drug chain stores in Japan. Genky DrugStores Co., Ltd. was founded in 1988 and is headquartered in Sakai, Japan.
